Travel thousands of miles, our hearts remain the same

There is no level road to start up a company. 

Although the road is difficult, our hearts remain the same and our mission is carried on our shoulders. Every step we take is not easy, thanks to the concern of leaders at all levels and the trust and support of friends from all walks of life, and thanks to the hard work of our colleagues . Happy eighth anniversary of Chongqing Precision Biotech!

At this moment, we will look back and re-examine the road we have traveled.

Facing the incidence trend of major human diseases, especially malignant tumors, Professor Qian Cheng deeply realized the technical direction of cancer treatment in the future. He understands the technology blockade and patent monopoly of giant pharmaceutical companies in developed countries in Europe and America, and is anxious for the development of China's biomedical industry and the health of cancer patients. He is worried that ordinary people may face foreign high-priced new drugs for cancer treatment in the future.

Eight years ago, after returning from studying abroad, Professor Qian Cheng founded Chongqing Precision Biotech Co., Ltd. together with Zhifei Bio, a domestic listed company, and officially entered the field of CAR-T therapy, becoming a new force of this field. At that time, the whole industry was in the embryonic stage, full of unknowns and challenges. But we anchor our goals, persevere and persist in science, technology and innovation. Today, Precision Biotech has become a leading enterprise in the field of CAR-T/NK in China. 

In the past eight years, we have deeply realized the hardships and difficulties of this track, but we have never given up.On the contrary, we have achieved rapid iterative upgrading of technology research and development and made progress towards industrialization.

Our R&D team has expanded from 30 people to over 300 people.The R&D base started from 4,000 ㎡, and after the transition to 18,000㎡, it will soon expand to 100,000 ㎡, because the stage is as big as our dreams.

The invention patents have achieved a breakthrough from 0 to 50, then to 100, and now over 130, and the layout is not limited to China.

Over 10 R&D pipelines for CAR-T products.

We have obtained implied licenses for four Class I CAR-T cell biological new drugs and nine indications.

Approved over 10 municipal platform qualifications and more than 20 national and local government scientific research transformation projects, and participated in the formulation of national clinical standards for cell drugs.

All these make us a representative of industrial technological innovation in the southwest region of China.

Over the past eight years, we have witnessed the growth and transformation of Precision Biotech, formed a business development model with technology as the background, innovation as the driving force, quality as the cornerstone and service as the guarantee. We also established the strategic goal of building a global scientific and technological biomedical enterprise. In this process, all colleagues have played an important role in their posts. Everyone's hard work and cooperation are the key for Precision Biotech to seize the opportunity of the times and achieve high-quality development.

Today, we are experiencing the storm of growth. No matter what kind of wind and rain, we can't stop our progress. In the future, we are poised to take a new step and start a new journey.

We will continue to adhere to our mission of "innovation for health", make innovations for cell therapy technology and focus on malignant tumor treatment. Based on the domestic and international dual-cycle strategy, we will implement the strategy of globalization of technical resources and internationalization of marketing, build a regional cell preparation base in China, explore the establishment of overseas R&D branches, and strive to build a biomedical enterprise with global competitiveness.